biotech / news / / The Sunday Times
Total revenue rose 8 per cent to $15.29 billion in the first three months of the year.
AstraZeneca's Q1 revenue reached $15.29 billion, surpassing analyst expectations of $14.9 billion.
KEY POINTS
- Positive phase III data was reported for four programs, including new molecular entities and tozorakimab.
- Tozorakimab showed reduced moderate-to-severe COPD exacerbations in two phase III trials versus placebo.
- AstraZeneca is maintaining its targets for 2024 and its $80 billion annual sales goal by 2030.
COMPANIES
Summarized by Newsio from The Sunday Times. How we summarize →